Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Qol Holdings Co., Ltd. (3034:JPX), powered by AI.
Qol Holdings Co., Ltd. is currently trading at ¥1,874. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Qol Holdings Co., Ltd. on Alpha Lenz.
Qol Holdings Co., Ltd.'s P/E ratio is 13.6.
“Qol Holdings Co., Ltd. trades at a P/E of 13.6 (undervalued) with solid ROE of 9.4%. 3Y revenue CAGR of 16.7% highlights clear growth momentum.”
Ask for details →Qol Holdings Co., Ltd. operates within the healthcare sector, primarily focusing on the pharmaceutical distribution industry in Japan. The company's core function involves providing drug dispensing and pharmacy management services, aiming to enhance convenience and accessibility of medicines to consumers. With an extensive network of pharmacies, Qol Holdings facilitates the efficient distribution of clinical drugs, over-the-counter medications, and health-related products. Additionally, the company engages in contract research and research and development services, fostering industry innovation. Qol Holdings significantly impacts the healthcare industry by integrating advanced technology solutions to streamline pharmacy operations and improve customer service. Its importance in the market stems from its commitment to delivering high-quality healthcare services and its role in supporting Japan's healthcare infrastructure through wider access to pharmaceuticals and personalized patient care initiatives. This not only enhances public health outcomes but also positions Qol Holdings as a key player in the pharmaceutical supply chain in Japan.
“Qol Holdings Co., Ltd. trades at a P/E of 13.6 (undervalued) with solid ROE of 9.4%. 3Y revenue CAGR of 16.7% highlights clear growth momentum.”
Ask for details →Qol Holdings Co., Ltd. (ticker: 3034) is a company listed on JPX in the Healthcare sector (Pharmaceutical Retailers). It has approximately 6,254 employees. Market cap is $70.1B.
The current price is 1,874 with a P/E ratio of 13.58x and P/B of 1.23x.
ROE is 9.40% and operating margin is 5.10%. Annual revenue is $264.0B.